
|Videos|March 23, 2021
Psychedelic Wellness
Author(s)Matt Stang
Early studies find psilocybin shows promise for some psychiatric disorders...
Advertisement
With numerous studies in stage 3 trials, the opportunities to leverage psilocybin for clinical care is likely to expand in the next few years. Matt Stang shares his excitement for the future of this agent as means to help more patients.
To learn more on psilocybin and earn CME credit, see
Mr Stang is the founder of
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Psychiatric Times
1
Kratom Component in Clinical Trial for Opioid Use Disorder
2
FDA Feedback Paves Way for New IND Filing for PT00114 in Generalized Anxiety Disorder
3
Why Cultural Context Matters in Psychiatric Assessment
4
NIDA Awards PleoPharma $6.5 Million Grant to Advance Phase 3 Trial of PP-01 for Cannabis Use Disorder
5









